文献速递物质与行为成瘾

急性大麻二酚给药降低酒精使用障碍患者的酒精渴求及线索诱导的伏隔核激活:双盲随机对照ICONIC试验

Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.
PubMed 文献 · Mol Psychiatry · 2024-12-12

ICONIC双盲随机对照试验在28名酒精使用障碍患者中比较单次800毫克大麻二酚(CBD)与安慰剂的效果。CBD组双侧线索诱导的伏隔核激活更低,在应激与酒精线索联合暴露后及fMRI线索反应任务中的酒精渴求均显著低于安慰剂组。CBD血浆水平与酒精渴求及伏隔核激活呈显著负相关,支持CBD作为酒精使用障碍治疗选择的潜力。

要点

  • 单次800毫克CBD较安慰剂显著降低酒精使用障碍患者双侧线索诱导的伏隔核激活。
  • CBD组在应激与酒精线索联合暴露后及fMRI线索反应任务中的酒精渴求显著低于安慰剂组。
  • CBD血浆水平与酒精渴求及左右伏隔核激活均呈显著负相关。

核心结论

  • CBD降低应激与线索诱导的酒精渴求并使伏隔核激活正常化的能力,有助于理解其临床效应的神经生物学基础,并支持其作为酒精使用障碍治疗选择的潜力。

研究设计与样本

  • 双盲随机对照ICONIC试验,比较单次800毫克大麻二酚与安慰剂在28名酒精使用障碍个体中的效果。
  • 结局包括线索诱导的伏隔核激活、应激与酒精线索联合暴露期间的酒精渴求、fMRI酒精线索反应任务中的渴求及CBD血浆水平。

主要发现

  • 接受CBD的个体双侧线索诱导伏隔核激活更低(左侧t(23)=4.906,p<0.001,d=1.15;右侧t(23)=4.873,p<0.001,d=1.13)。
  • CBD组在应激与酒精线索联合暴露后报告的酒精渴求显著更低(Fgroup(1,26)=4.516,p=0.043,eta2=0.15)。
  • CBD组在fMRI线索反应任务中的酒精渴求显著更低(Fgroup(1,24)=6.665,p=0.015,eta2=0.23)。
  • CBD组CBD水平显著更高(t(25)=3.808,p<0.001,d=1.47)。
  • CBD水平与线索暴露实验中的酒精渴求(r=-0.394,pFDR=0.030)、fMRI中的酒精渴求(r=-0.389,pFDR=0.030)及左右伏隔核激活(左侧r=-0.459,pFDR=0.030;右侧r=-0.405,pFDR=0.030)呈显著负相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although alcohol use disorder (AUD) is highly prevalent, only a few medications are approved for its treatment leaving much room for improvement. Cannabidiol (CBD) might be a particularly promising candidate, with preclinical data suggesting that CBD is effective in targeting AUD symptoms and disease processes that drive alcohol use and relapse, due to its anti-craving, stress-reducing, and anti-compulsive effects. Here we report data from the double-blind randomized controlled ICONIC trial that compared the effects of a single dose of 800 mg cannabidiol against placebo (PLC) in N = 28 individuals with AUD. Cue-induced nucleus accumbens (NAc) activation, alcohol craving during a combined stress- and alcohol cue exposure session, as well as craving during an fMRI alcohol cue-reactivity task and CBD plasma levels served as outcomes. Individuals receiving CBD showed lower bilateral cue-induced NAc activation (tleft_NAc(23) = 4.906, p < 0.001, d = 1.15; tright_NAc (23) = 4.873, p < 0.001, d = 1.13) and reported significantly lower alcohol craving after a combined stress- and alcohol cue exposure session (Fgroup(1,26) = 4.516, p = 0.043, eta2 = 0.15) and during the fMRI cue-reactivity task (Fgroup(1,24) = 6.665, p = 0.015, eta2 = 0.23). CBD levels were significantly higher in the CBD group (t(25) = 3.808, p < 0.001, d = 1.47) and showed a significant negative association with alcohol craving during the cue exposure experiment (r = -0.394, pFDR = 0.030) and during fMRI (r = -0.389, pFDR = 0.030), and with left and right NAc activation (rleft_NAc = -0.459, pFDR = 0.030; rright_NAc = -0.405, pFDR = 0.030). CBD's capacity to reduce stress- and cue-induced alcohol craving and to normalize NAc activation - a region critical to the pathophysiology of AUD - contribute to understanding the neurobiological basis of its clinical effects and support its potential as a treatment option for AUD. Clinical Trials Registry: DRKS00029993.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Zimmermann S, Teetzmann A, Baeßler J, et al. Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial. Mol Psychiatry. 2024. PMID: 39668256. doi:10.1038/s41380-024-02869-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。